News

News

  • Making Sense of it all: A Review of Recent Studies on the Role of Aspirin in Preventing Heart Disease and how ADAPTABLE fits in the Picture

    Aspirin is a drug that has been used for decades to prevent the occurrence of a heart attack or stroke by thinning blood so clots do not form. Doctors recommend either high-dose (325 mg) or low-dose (81 mg) aspirin and its use across the United States is fairly balanced between high-dose and low-dose aspirin. The ADAPTABLE ...
  • When Patients Partner with Researchers: Desiree’s Perspective

    In ADAPTABLE, patients are more than study participants, they are partners with researchers and clinicians to improve cardiovascular health for all patients and those who care for them. Adaptors are patient representatives who have been involved in ADAPTABLE from the beginning. The Adaptors team works alongside the study team, participating in team meetings and providing ...
  • Importance of Diversity in Clinical Research

    The main phases of a clinical research study include: 1) identification and recruitment of study participants, 2) data collection and monitoring, 3) analysis of study results, and 4) distribution of study findings. ADAPTABLE team members are currently focused on the first two phases. In this article, we explore why it is important that people of ...
  • Taking a Real-Time Approach to Identifying and Enrolling Patients in the ADAPTABLE Study

    The Duke Heart Center, the second highest enrolling site in the ADAPTABLE study, recently celebrated a milestone with more than 1,000 patients enrolled. In this article, the team shares how they leverage their electronic health record (EHR) system to streamline the screening process for this pragmatic study designed to answer what is the best daily ...
  • ADAPTABLE Study Team Shares Patient Engagement Experiences in CardioSmart Pavilion at American College Cardiology Conference

    Jacqueline Alikhaani, a rare disease heart patient and partner on the ADAPTABLE Study, is passionate about the value and impact of novel clinical research studies. Alikhaani is especially passionate about studies that leverage electronic health records and common data resources, and includes patient input at every critical step in the process. “One of the special ...
  • Celebrating Your Heart and February

    The ADAPTABLE Team is excited for February, a month-long celebration of heart-health awareness. This a great time to think about what is known about heart disease, how heart-healthy choices can make a difference, and the potential impact of the results from the ADAPTABLE Study for patients and their doctors. Heart Disease Heart disease is the leading cause ...
  • When Patients Partner with Researchers: Bill’s Perspective

    In ADAPTABLE, patients are more than study participants, they are partners with researchers and clinicians to improve cardiovascular health for all patients and those who care for them. Adaptors are patient representatives who have been involved in ADAPTABLE from the beginning. The Adaptors team works alongside the study team, participating in team meetings and providing ...
  • ADAPTABLE’s Patient-Researcher Partnership Serves as a Model of Engagement

    The ADAPTABLE Study is featured as a model of patient engagement in Applied Clinical Trials. As patients take more active roles in decision-making about health, healthcare, clinical trials, and regulatory activities, their influence has changed how sponsors and researchers view patient involvement in clinical research.Once regarded as “subjects” who had research performed on them, patients are ...
  • Heart Patients Help Doctors Determine Best Aspirin Dose

    Doctors have known for decades that taking aspirin can reduce the risk for future heart attacks and strokes in people with cardiovascular disease. What is less clear is which dose is best. Participants in a new kind of clinical trial are helping them find out. Which Aspirin Dose Is Best? Some doctors prescribe a “baby aspirin” (81mg) ...
  • 2017: Year in Review

    The ADAPTABLE Study team reflects on the many accomplishments and milestones throughout 2017 — a year of record enrollment, new network collaborations, and actively engaging with and sharing the voice of study participants. We wish you the best in 2018 and look forward to continuing to build a community where participants, researchers, and clinicians partner ...

tertiary sidebar container